Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Lung Cancer (Amsterdam, Netherlands)|February 20, 2026
Patterns of progression in patients with synchronous oligometastatic non-small cell lung cancer after systemic and local radical treatmentValentina Bartolomeo, Mandy Jongbloed, Jarno W J Huijs, et al.
The European Respiratory Journal|June 11, 2026
ERS statement: Core outcome set for trials evaluating the management of community-acquired and nosocomial pneumonia in adultsMarkus Fally, Catia Cilloniz, John Linnell, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2025
AGREE-II appraisal of lung cancer management clinical practice guidelines by the OPTIMA consortiumSindhu Bhaarrati Naidu, Amyn Bhamani, Charlotte Murray, et al.
Lung Cancer (Amsterdam, Netherlands)|September 4, 2025
Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastasesJarno W J Huijs, Anna M Sadowska, Juliette H R J Degens, et al.
The European Respiratory Journal|March 15, 2014
Glucocorticoids induce the production of the chemoattractant CCL20 in airway epitheliumG Jan Zijlstra, Fatemeh Fattahi, Dennie Rozeveld, et al.
American Journal of Respiratory Cell and Molecular Biology|September 6, 2014
Cigarette smoke-induced damage-associated molecular pattern release from necrotic neutrophils triggers proinflammatory mediator releaseIrene H Heijink, Simon D Pouwels, Carin Leijendekker, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|January 1, 2016
Cigarette smoke-induced necroptosis and DAMP release trigger neutrophilic airway inflammation in miceSimon D Pouwels, G Jan Zijlstra, Marco van der Toorn, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2026
Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumabYan Wang, Laura H Bukkems, Johan G C van Hasselt, et al.
ERJ Open Research|October 21, 2022
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancerRolof G P Gijtenbeek, Vincent van der Noort, Joachim G J V Aerts, et al.
Plos One|August 12, 2022
Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patientsAbraham Rutgers, Peter E Westerweel, Bronno van der Holt, et al.
Pageof 6